Participating in the presentations and discussions will be members of the
Raju Mohan , PhD, Founder, Chief Executive Officer and DirectorWilliam Sandborn , MD, President and Chief Medical OfficerJohn Nuss , PhD, Chief Scientific OfficerJames Krueger , MD, PhD, Director of the Milstein Medical Research Program andD. Martin Carter Professor in Clinical Investigation atRockefeller University inNew York
A live webcast of the event will be available in the “Investors” section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of the event.
About
Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes three internally discovered clinical programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in
Investor Relations Contact
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com
![](https://ml.globenewswire.com/media/Mzg0MmY4ZGUtYWQ4MC00MTQzLTg5ODctNjBiNDMyZWUwYzY5LTEyMjIyNzg=/tiny/Ventyx-Biosciences-Inc-.png)
2023 GlobeNewswire, Inc., source